Parkinson's Disease/Movement Disorders News

To mark this April as Parkinson’s Awareness Month, the Parkinson’s Foundation has created the #ABCsofPD to provide information about relevant symptoms, statistics and treatments.

A Swiss-based medical technology company has announced a partnership with Biogen to advance a digital biomarker platform involved in a planned clinical trial for BIIB122, a novel therapeutic to treat Parkinson’s disease.

A United Kingdom-based clinical-stage biotech company has announced commencement of a first-in-human clinical trial of a selective central nervous system-penetrant compound to treat Parkinson’s disease.

Compared with oral administration, continuous subcutaneous infusion of carbidopa/levodopa was linked to nearly 2 more hours of “on” time without dyskinesia in adults with Parkinson’s disease, data from The Lancet Neurology show.

CuraSen Therapeutics has announced positive data from a phase 2a study of its combination adrenergic activator, CST-2032/CST-107, for patients with mild cognitive impairment or mild dementia from Alzheimer’s or Parkinson’s disease.

A New York-based biopharmaceutical company has received a grant from Cure Parkinson’s to initiate a phase 2 clinical trial investigating dapansutrile, an oral small molecule, as a disease-modifying therapy for Parkinson’s disease.

Kathryn P. L. Moore, MD, MSc, assistant professor of neurology at Duke University School of Medicine, discusses therapies in the pipeline that are working to target the cause of Huntington's disease.

Kathryn P. L. Moore, MD, MSc, assistant professor of neurology at Duke University School of Medicine, discusses valbenazine, a recent approval in Huntington's disease care.

Kathryn P. L. Moore, MD, MSc, assistant professor of neurology at Duke University School of Medicine, discusses risk factors that can be addressed early in Huntington's disease treatment, such as smoking and excessive alcohol intake.

Kathryn P. L. Moore, MD, MSc, assistant professor of neurology at Duke University School of Medicine, emphasizes the need for Huntington's disease awareness among providers and the general public.